All In Biotech

Drug Trial Radar · NCT05902169

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Jan 29, 2024

Primary completion

Jan 28, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
CarTheraIndustry
Sponsor type
Industry
First posted
Jun 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated. The SonoCloud-9 (SC9) is an investigational device using ultrasound technology and specially developed to open the BBB in the area of and surrounding the tumour. The transient opening of the BBB allows more drugs to reach the brain tumour tissue. Carboplatin is a chemotherapy that is approved to treat different cancer types alone or in combination with other drugs, and has been used in the treatment of glioblastoma. Despite its proven efficacy in the laboratory on glioblastoma cells, carboplatin does not readily cross the BBB in humans. A clinical trial has shown that in combination with the SonoCloud-9, more carboplatin can reach the brain tumour tissue. The objective of the proposed trial is to show that the association - carboplatin with the SonoCloud-9 - will increase efficacy of the drug in patients with recurrent glioblastoma.

Conditions

  • Glioblastoma
  • Recurrent Glioblastoma
  • GBM

Interventions

  • SonoCloud-9 (SC9)Device

    Implantation of SC9 device and repeat activation at constant acoustic pressure

  • CarboplatinDrug

    Dose of carboplatin AUC 5 mg/ml.min-1 calculated using Calvert's formula: Dose (mg) = target AUC (mg/mL x minute) x \[glomerular filtration rate (GFR) mL/minute + 25\].

  • LomustineDrug

    Dosed and administered per labelling.

  • TemozolomideDrug

    Dosed and administered per labelling.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to 24 months

Locations

56 sites in 11 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Kaiser Permanente

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • Sutter Health - California Pacific Medical Center

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • UCHealth

    Aurora, Colorado

  • Mayo Clinic of Jacksonville Florida

    Jacksonville, Florida

  • Miami Cancer Institute

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Indiana University Health

    Indianapolis, Indiana

  • John Hopkins University

    Baltimore, Maryland

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Weill Cornell Medicine

    New York, New York

  • NewYork-Presbyterian / Columbia University Irving Medical Center

    New York, New York

  • Lennox Hill Hospital

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Neurological Institute Brain Tumor Centre Taussig Cancer Cente

    Cleveland, Ohio

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Texas Houston Health Science Center

    Houston, Texas

  • University of Utah, Hunstman Cancer Institute

    Salt Lake City, Utah

  • Medizinische Universitaet Innsbruck

    Innsbruck, Austria

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • CHU de Liège

    Liège, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Hôpital Neurologique Pierre Wertheimer

    Bron, France

  • Hôpital de La Timone

    Marseille, France

  • Hôpital de la Pitié-Salpêtrière

    Paris, France

  • Hôpital Foch

    Suresnes, France

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany

  • Neurochirurgie uniklinik Köln

    Cologne, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitätsklinikum Essen Klinik für Neurologie

    Essen, Germany

  • University Hospital Munster

    Münster, Germany

  • Ospedale Bellaria

    Bologna, Italy

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.